Chronic cough
Drug research and approvals for chronic cough: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 29 studies of chronic cough are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 29
- Trials authorized in Canada: 18
- FDA orphan approvals: 0
- EU medicines: 1
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsNCT07868419 · Phase 3 · Trevi Therapeutics · starts Sep 30, 2026
- A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or…NCT07690059 · Phase 2 · Sensory Cloud, Inc. · starts Jul 13, 2026
- The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)NCT07671924 · Phase 2 · Trevi Therapeutics · starts Jun 22, 2026
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsNCT07671911 · Phase 3 · Trevi Therapeutics · starts Jun 29, 2026
- Remodelling of the Lower Airways in Chronic CoughNCT07659860 · Not reported · Medical University of Warsaw · starts Oct 1, 2022
- Finnish Children´s Protracted CoughNCT07582549 · Phase 3 · Tampere University Hospital · starts Dec 22, 2025
- Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in…NCT07566117 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Efficacy of Behavioral Therapy for Chronic Refractory CoughNCT07488598 · Not applicable · Assiut University · starts Mar 10, 2026
- Wenjuanxing-Based Multidimensional Etiologic Screening and Clinical Validation of Chronic Cough in ChildrenNCT07306637 · Not reported · Shanghai Children's Medical Center · starts Jan 7, 2026
Approved 1
- GefapixantP2X purinoceptor 3 antagonist
Phase 1 or earlier 2
- CamlipixantP2X purinoceptor 3 antagonist
- Eliapixant
How its trials ended
119 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 34 whose ending is known, 65% met their primary endpoint, 9% missed it and 26% stopped early.
- Completed, result not reported3832%
- Ongoing2924%
- Met its primary endpoint2218%
- Status unknown1815%
- Stopped: enrollment or feasibility43%
- Missed its primary endpoint33%
- Stopped: other or unclear33%
- Stopped: lack of efficacy22%
| Sep 28, 2026 | A randomized, double-blind, placebo-controlled twelve-week fixed-dose study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the…Nalbuphine | Trevi Therapeutics | Pending |
| May 22, 2026 | A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment…Nalbuphine | Trevi Therapeutics | Ongoing |
| Nov 27, 2025 | A 2x2 factorial, randomized, open-label trial to evaluate neuromodulators and cough control therapy in patients with refractory or unexplained chronic cough:…Morphine / Pregabalin | McMaster University | Pending |
| Sep 3, 2025 | Understanding the role of airway mucus occlusions in Canadians with asthma, COPD and chronic cough (CANMUC)Hyperpolarized XENON-129 | McMaster University | Pending |
| Feb 11, 2025 | A phase 3, 24-week, randomized, double-blind, placebo-controlled, parallelarm efficacy and safety study with open-label extension of BLU-5937 in adult…Camlipixant (GSK5464714, BLU-5937) | BELLUS Health | Ongoing |
| Sep 26, 2024 | A phase 2b, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of taplucainium inhalation powder (NOC-110) in…Taplucainium (NOC-110/NTX-1175) | Nocion Therapeutics | Ongoing |
| Aug 21, 2023 | A randomized, double-blind, placebo-controlled, parallel, 4-arm dose ranging study of the safety and efficacy of nal er tablets for the treatment of cough in…Nalbuphine | Trevi Therapeutics | Closed |
| Aug 11, 2023 | A phase 2, double-blind, randomized, placebo-controlled, two-period crossover efficacy and safety study of nalbuphine er tablets for the treatment of…Nalbuphine | Trevi Therapeutics | Closed |
| Nov 16, 2022 | A phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of BLU-5937 in adult…Camlipixant (BLU-5937) | BELLUS Health | Closed |
| Mar 29, 2021 | Mepolizumab for the treatment of chronic cough with eosinophilic airways diseaseNucala | McMaster University | Pending |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 15, 2023 | LyfnuaGefapixant | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA